Claims for Patent: 8,475,831

Summary for Patent: 8,475,831

Title:	Treatment of ophthalmic conditions
Abstract:	Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.
Inventor(s):	Sancho; Alberto Osio (Colonia Bosques de las Lomas, MX)
Assignee:	Osio Corporation (Coronado, CA)
Application Number:	10/582,728
Patent Claims:	1. A non-invasive method for treating presbyopia, the method comprising steps of: providing a contact lens, providing eye drops comprising an effective amount of hyaluronidase and collagenase, wherein the collagenase is not matrix metalloproteinase 1 or matrix metalloproteinase 2; applying contact lens to an eye of a patient suffering from presbyopia; and applying the eye drops to the eye of patient; wherein the treatment corrects the patient's near vision without diminishing substantially the patient's far vision, and whereby the treatment results in corrected vision for at least 6 months. 2. The method of claim 1, wherein the contact lenses are commercially available. 3. The method of claim 1, wherein the contact lens is an extended wear contact lens. 4. The method of claim 1, wherein the eye drops further comprise at least one agent selected from the group consisting of enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinases, vasocontrictors, anti-viral agents, anti-fungal agents, anti-inflammatory agents, and lubricants. 5. The method of claim 1, wherein the eye drops further comprise a polymer. 6. The method of claim 5, wherein the polymer is selected from the the group consisting of methylcellulose, cellulose, and polyvinylalcohol and polyethylene glycol. 7. The method of claim 1, wherein the eye drops are in the form of a liquid. 8. The method of claim 1, wherein the eye drops are in the form of a gel. 9. The method of claim 1, wherein the eye drops are hypertonic. 10. The method of claim 1, wherein the eye drops are hypotonic. 11. The method of claim 1, whereby the treatment results in the corrected vision for at least 1 year. 12. The method of claim 1, wherein the eye drops comprise about 0.1% to about 5% hyaluronidase; about 0.1% to about 6% collagenase; and, optionally, a polymer selected from the group consisting of cellulose, methylcellulose, polyvinylalcohol and polyethylene glycol. 13. The composition of claim 12, wherein the composition is hypertonic. 14. The composition of claim 12, wherein the composition is hypotonic. 15. The composition of claim 12, wherein the eye drops further comprise at least one agent selected from the group consisting of enzymes, anesthetics, vitamins, zinc, antibiotics, anti-allergic agents, carbamide, cytokinase, vasoconstrictors, anti-viral agents, anti-fungal agents, anti-inflammatory agents and lubricants. 16. The method of claim 1, wherein the eye drops are in the form of a spray. 17. The method of claim 8, wherein the gel is a semi-solid gel. 18. The method of claim 1, wherein the contact lens is a gas permeable contact lens.

Details for Patent 8,475,831

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2023-12-19
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2023-12-19
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2023-12-19